Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Advisory Committees Cardiology FDA

TransMedics Faces 2nd Panel Date Postponement

Will the third time be the charm?

Executive Summary

The company said the postponement will give the US FDA additional time to review trial data.

You may also be interested in...



Panel Back On Track For TransMedics’ Heart Device After Missing A Few Beats

The US FDA will host an advisory committee webcast to discuss approval of the company’s new heart transplant device a year after it was originally planned.

TransMedics Heart Transplant Tool Lands FDA Panel Date After 6-Month Delay

The US agency’s circulatory system devices panel will take up the company’s heart transplant tool in an October virtual session.

News We're Watching – 27 January

This feature compiles news briefs on a range of US regulatory and legal happenings. This week: Medtronic seeks HeartWare batteries; companies sign health equity pledge; insulin dosing app cleared; recall on field decontamination kits; and the renewal of an FDA panel. 

Table

View full table

Topics

Tags:
Advisory Committees Cardiology FDA
Latest Headlines

UK MHRA’s New And Increased Medtech Fees In Force in April

EU Digital Tech Trade Body Weighs In On Medical Device ‘Over-Regulation’ Risk

Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical

Updated GUDID Data Shows Product Details For 4M Devices

See All
UsernamePublicRestriction

Register

MT142840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By